Effect of dietary purines on the pharmacokinetics of orally administered ribavirin

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 661-667

  Li, Linghui ^a   Koo, Seok Hwee ^a   Limenta, Lie Michael George ^a   Han, Li ^a,b   Hashim, Khadijah Binte ^b   Quek, Hung Hiang ^b   Lee, Edmund Jon Deoon ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SCHOOL OF APPLIED SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Dietary purine; HCNT2; Pharmacokinetics; Ribavirin

Indexed keywords

PURINE; RIBAVIRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PURINES; RIBAVIRIN;

EID: 67049086251     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009335002     Document Type: Article

References (23)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus riba-virin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
4. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005;41:275-279.
5. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepatol. 2004;11:84-87.
6. Ribavirin [dataonfile]. Basel, Switzerland:ICNPharmaceuticals; 1997.
7. Ribavirin [data on file]. Kenilworth, NJ: Schering-Plough Corporation; 1998.
8. Ribavirin (Copegus) [prescribing information]. Nutley, NJ: Roche; 2002.
9. Ribavirin (Rebetol) [prescribing information]. Kenilworth, NJ: Schering-Plough Corporation; 2004.
10. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004;447: 728-734.
11. Shin HC, Landowski CP, Sun D, et al. Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum. Biochem Biophys Res Commun. 2003;307:696-703.
12. Patil SD, Ngo LY, Glue P, Unadkat JD. Intestinal absorption of ribavirin in preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res. 1998;15:950-952.
13. Paroni R, Del Puppo M, Borghi C, Sirtori CR, Galli Kienle M. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite l,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1989;27: 302-307.
14. Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987;41:546-555.
15. Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. J Clin Pharmacol. 2006;46:559-566.
16. Wang J, Su SF, Dresser MJ, Schaner ME, Washington CB, Giacomini KM. Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol. 1997;273(pt 2):F1058-F1065.
17. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, Young JD. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotrans-porter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol. 1998;15:203-211.
18. Owen RP, Gray JH, Taylor TR, et al. Genetic analysis and functional characterization of polymorphisms in the human con-centrative nucleoside transporter, CNT2. Pharmacogenet Genomics. 2005;15:83-90.
19. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2003.
20. Glue P. The clinical pharmacology of ribavirin. Semin Liv Dis. 1999;19(suppl l):17-24.
21. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004;117:163-168.
22. Nguyen MH, Keeffe EB. Chronic hepatitis B and hepatitis C in Asian Americans. Rev Gastroenterol Disord. 2003;3:125-134.
23. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology. 2002)36:1259-1265.